Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2024 Aug 19;19(8):e0308966. doi: 10.1371/journal.pone.0308966

Use of tobacco during COVID-19: A qualitative study among medically underserved individuals

Tamar Klaiman 1,*, Nsenga Farrell 1, Dorothy Sheu 1, Aerielle Belk 1, Jasmine Silvestri 1, Jannie Kim 2, Ryan Coffman 3, Joanna Hart 1
Editor: Enkeleint A Mechili4
PMCID: PMC11332913  PMID: 39159172

Abstract

The COVID-19 pandemic produced stress for people around the world. The perception that tobacco can be a coping tool for stress relief suggests that the conditions during the COVID-19 pandemic can provide insight into the relationship between stress and tobacco use patterns, particularly among those most at risk for severe COVID-19 disease. The goal was to identify the impacts of the COVID-19 pandemic on tobacco use and preparedness for smoking cessation among individuals who smoke and are older and medically underserved. We conducted in-depth interviews with 39 patients to learn about individuals’ smoking behavior during the COVID-19 pandemic. We used a modified grounded theory approach to code and analyze all qualitative data. We conducted thematic analysis to identify key factors associated with smoking behaviors during COVID-19. Our results indicated that increases in perceived stress and social isolation may have been associated with increased tobacco use during the COVID-19 pandemic. Pandemic-related social isolation contributed to increases in smoking, despite respondents being concerned about the severity of COVID-19. While many respondents felt that smoking relieved their stress from the pandemic, they appeared unaware of the stress-inducing properties of tobacco use. Our findings indicate that pandemic-related stress impacted smoking behavior among older, medically underserved smokers. Results may assist clinicians in addressing the role of tobacco use in response to highly stressful events. Smoking cessation strategies should consider the implications of stress on smoking behavior, including smoking relapse in response to highly stressful events–particularly for medically underserved populations.

Introduction

The COVID-19 pandemic produced exceptional amounts of prolonged financial, social, physical, and emotional stress on the global community [1]. The persistent, but incorrect, perception that tobacco can be a coping tool for stress relief [24] suggests that the conditions during the COVID-19 pandemic can uniquely provide important insight into the relationship between complex stress and tobacco use patterns.

There is minimal existing knowledge of how patients navigated and managed contextual forces, including stress, that may have influenced their tobacco use behaviors and attitudes and led to variations in use patterns during the pandemic [57]. Existing evidence of tobacco use during the COVID-19 pandemic suggests that there was variability in whether individuals increased or decreased their use, without a consistent pattern [8]. For example, survey-based studies investigating tobacco use during the COVID-19 pandemic have consistently revealed that approximately a quarter of individuals increased tobacco use, approximately a quarter decreased tobacco use, and approximately half experienced no change in their use [912] Yet, the evidence to date is limited and does not sufficiently explore the mechanisms or causes underlying these patterns [1, 1315] which are important for leveraging the knowledge gained to improve tobacco treatment efforts. The social distancing restrictions enacted during COVID-19 changed and may have restricted access to health care, including tobacco treatment, but may have also reduced or changed access to tobacco products.

Further, while there is evidence that age and perceived risk of severe COVID-19 disease was associated with tobacco use patterns, there has been little focused attention to the tobacco use patterns of those most at risk for severe COVID-19 disease [5, 16, 17]. Individuals who are low income and historically marginalized were at especially high risk for severe COVID-19 disease, unemployment, and reduced access to health care [18, 19]. These same populations are also disproportionately impacted by tobacco use resulting from targeted tobacco marketing strategies, inequitable access to tobacco treatment, and chronic stress [20]. For example, tobacco companies market tobacco to low-income populations and people of color [21], distribute cigarettes to children in low income neighborhoods [22], support more retailers and more retail window advertising in low income communities [23], discount prices to improve uptake [24], and have increased the nicotine concentration of cigarettes over time [25, 26]. Prior research has also identified contextual factors such as social norms, economic structures, and high levels of stress from racial discrimination and poverty as contributing to tobacco use among Black and low-income groups [27]. The pervasive structural stress among these medically underserved groups was further amplified during the COVID-19 pandemic. Therefore, the primary goal of this project was to identify the impacts of the COVID-19 pandemic on tobacco use and preparedness for smoking cessation among individuals who smoke and who are older and medically underserved. Utilizing in-depth qualitative interviews allows contextualization around the patterns seen in the quantitative data that has been published.

Methods

We conducted a qualitative study consisting of in-depth interviews with older, medically underserved adults to learn about their smoking behavior during the COVID-19 pandemic. We recruited participants from September 30, 2020, to September 14, 2021 –during the height of the pandemic through the initiation of vaccines. Patient participants were recruited through multiple sampling strategies. First, we utilized the electronic health record of the University of Pennsylvania Health System (UPHS) to identify potential participants. We randomly selected UPHS outpatients who were at least 50 years old and had electronic health record (EHR)-documented daily tobacco use. We sent batches of mailed recruitment letters in randomized fashion to 25 to 50 potentially eligible patients at a time asking them to complete an online screening survey to determine eligibility. Using data available in the EHR, we purposefully sampled for rurality based on ZIP code (i.e., a Rural-Urban Community Area score of ≥2) during later periods of recruitment (i.e., subsequent batches of letters) given that we lacked sufficient rural representation in our initial group of participants and to ensure diverse representation of perspectives.

Second, we approached potential participants through our established partnership with a local, Hispanic serving non-profit agency. Trained staff—as part of the organization’s COVID-19 Mobile Response Unit outreach to low-income urban and rural areas in northeastern and central Pennsylvania—recruited and assessed for eligibility among individuals engaging in their outreach sessions. Third, we relied on snowball sampling, in which participating patients provided information about the study to acquaintances who were then assessed for eligibility using the same approach.

After providing verbal informed consent for participation and documenting it in the recruitment spreadsheet, enrolled individuals participated in a structured telephone interview that was audio recorded with their permission. Consents were collected verbally because all interviews were conducted via telephone. The University of Pennsylvania IRB approved all procedures, including a verbal telephone consent procedure. Participants were given a full description of the study and agreed to participate after expressing understanding of the study procedures. Eligible individuals were using tobacco daily, 50 to 80 years old, and represented at least one of the following demographic groups: reported household income less than 200% of the federal poverty line based on household size, less than a high school level of formal educational attainment, self-identified as Black or African American, Hispanic or Latinx, and/or reported living in a rural area. Only those who spoke English or Spanish were included. Patients received $50 USD for their participation. Interviews were conducted in English or Spanish based on participants’ preferences.

The interview guide (Supplement 1) was developed through literature reviews, in consultation with clinicians who treat lung disease and/or tobacco use disorder, and a stakeholder advisory committee consisting of patient and community advocacy groups, patients, clinicians, and health system leaders. The interviews focused on (1) smoking behavior prior to and during the COVID-19 pandemic, (2) perceptions about the impact of smoking on the development and severity of COVID-19, (3) barriers and facilitators for tobacco treatment prior to and during the COVID-19 pandemic, and (4) stressors and lifestyle changes during the COVID-19 pandemic. All questions were open ended and reflected high-level concepts (such as motivation, or behavior), and all respondents were asked questions focused on these core topics. Recruitment continued until thematic saturation was reached–no new themes arose after three additional interviews [28]. A professional transcription and translation company transcribed the audio recordings of the interviews and, if needed, translated the text to English from Spanish. The transcription process also removed identifying information in preparation for analysis. The Institutional Review Board of the University of Pennsylvania approved all procedures (protocol #843833).

Analysis

We used a modified grounded theory approach to code and analyze all qualitative data. Investigators inductively developed a preliminary codebook based on emerging themes and deductively based on behavioral health constructs identified in the literature review (JH), including beliefs about consequences, motivations and goals, environmental context, and resources. All coding was overseen by a Senior Qualitative Research Scientist (TK). Research staff trained in qualitative methods conducted the coding. The codebook was iteratively revised as additional transcripts were reviewed. Research staff used the codebooks to code all transcripts in NVIVO 12.0, with 20% coded by two staff members to assess reliability. Research staff met at least weekly during coding to resolve conflicts. Any disagreements were discussed until consensus was reached with iterative revision of the codebook and review of previously coded transcripts as necessary. Theme sheets were developed for each of the identified themes, and weekly meetings were held with study staff to analyze results within and between themes. The University of Pennsylvania IRB approved this study (protocol #843833).

Results

Thirty-nine patients completed interviews. Respondent demographics are noted in Table 1.

Table 1. Respondent demographics.

Respondents N = 39 (%)
Age
50–54 6 (15.4)
55–59 7 (17.9)
60–64 13 (33.3)
65–69 10 (25.6)
70–74 2 (5.1)
75+ 1 (2.6)
Gender
Man 20 (51.3)
Woman 19 (48.7)
Race
White or Caucasian 13 (33.3)
Black or African American 19 (48.7)
Asian or Asian American 0 (0.0)
Native American 0 (0.0)
Other 7 (17.9)

Unrelated to the pandemic, most respondents had attempted to quit tobacco at least once, yet all resumed smoking. Participants identified triggers such as increased anxiety, stress, grief, other substances (e.g., coffee or alcohol), and general boredom as precipitating smoking relapse even after prolonged abstinence.

I stopped smoking–I forget when it was, I think it was in May. I was doing good, and I think my brother-in-law passed in September…and he was my favorite brother-in-law, and when he passed away, it made me feel so bad. So, that’s how I started back smoking. (Respondent 115)

Like if I drink coffee, like every time I drink coffee throughout the day. (Respondent 033)

Well, I went out drinking and… someone was smoking and you know, I was like, “Oh, let me get one.” They were like, “Oh no, you don’t smoke anymore?” And I was like, “No, give me one.” And that’s what happened. (Respondent 106)

Tobacco was frequently used by participants as a tool for stress relief. Respondents felt that smoking helped them to calm down, particularly after stressful events or managing grief and anger. The reliance on tobacco as a coping tool for stress was both a precipitant of relapse and a reason to continue use. Some framed their tobacco use for this purpose as distinct from more general dependence on nicotine or smoking.

You know, like… I don’t know, many people don’t understand it, but it really does calm you down. Well, some people need it because they’re regular smokers, but in my case, I see it as a relaxant, for me. (Respondent 022)

… I did good for six months, and then one day I got angry, and I bought a packet of cigarettes and did myself in. (Respondent 107)

I once stopped smoking, and I stopped for… I’m not lying, for around 8 or 9 months, but when my mom passed away, when I lost my mom, I went back to smoking. I haven’t quit ever since. (Respondent 024)

The impact of COVID-19 on reporting smoking behavior was varied among respondents. Potential pandemic-era structural barriers to accessing tobacco products, such as stay-at-home orders and social distancing requirements, did not play a major role in tobacco purchase or use patterns among our respondents. For example, almost all respondents did not have trouble buying cigarettes from local convenience stores using their same purchasing behaviors. However, participants did report following recommended COVID-19 mitigation measures to reduce their risk of contracting the virus, such as hand washing, mask wearing, and avoiding crowds.

I go to the store and I buy cigarettes by the carton. So, that’s the same way I do now. (Respondent 217)

I could be out of cigarettes, and make it for a couple of hours, and then it wouldn’t matter what time of the day or night it was. [laughs] If I was still awake, I’d go out and get a pack. So, I basically purchase them the say way, except now I have to put a mask on when I got into the store. (Respondent 158)

Well, it basically hasn’t changed… we have what they call, "Cigarette Outlet Stores." … They sell cigarettesJust one particular one that I know is kind of … tucked away, and it’s never very crowded when I go there. So, it’s—it’s nice in that respect because you’re not around a whole lot of other people, because the store is at least—well, see that’s another change in my routine too is, I stay away from the stores on Fridays, Saturdays, and Sundays. I will prefer to go usually on a Tuesday, if I can, because I find that Tuesday for some reason, just in this general area where I live, that it’s not as crowded on Tuesday as it is any other day. (Respondent 156)

Some respondents reported increasing their tobacco use directly due to pandemic-related changes. These included increased anxiety, boredom, or having more unfilled or leisure time due to COVID-related activity restrictions and social distancing. The primary source of anxiety identified by respondents was an increase in social isolation due to the pandemic.

… I’ve always kind of like had a problem with smoking… I can say, oh, it wasn’t as bad as it is now. You know… being …in the house, and you kind of feel like closed in. And so, it’s kind of like… it was kind of like comforting for me. So, I think I’m smoking more… than before. (Respondent 033)

I would say like on average, like when I’m home more due to the pandemic, I’ve been smoking more. (Respondent 141)

I find myself—it seems that I’m smoking more because of [the COVID-19 pandemic], with the stress and being in the house, and not being able to do things, and being around people. (Respondent 132)

Either, either boredom, which is heightened during, um COVID, books or boredom. Or maybe frustration, you know, maybe frustration that I’m not doing very much, which I guess is kind of like boredom. (Respondent 120)

Many respondents believed that, if contracted, their severity of COVID-19 illness would be worse due to tobacco use or due to co-morbidities also tied to tobacco use. This caused increased stress and anxiety among participants who worried about their susceptibility to COVID-19 and the immediate health threat of the virus, including heightened attention to possible mortality. This perception was based on their recognition that tobacco is a pulmonary toxin and COVID-19 is a respiratory virus.

I have a cigarette addiction, but I also need to know that I’m not a millionaire and I can’t spoil myself as I used to. I used to not care because, I was able to touch every door and touch anything, now you can’t touch everything and you need to be careful of someone touching you from behind because… It’s gotten me a bit more anxious, because I start thinking, “what if this virus can’t be cured or something?” You know? So one just gets sort of scared. (Respondent 022)

And people who smoke are more susceptible to catch that thing, because your lungs aren’t strong enough to fight off that disease, because people who smoke, carry nicotine in their lungs and that makes it harder to breathe. (Respondent 024)

I’ve figured that at some point in the early—early stages of the pandemic, when it was first being announced, I smoke more, and then I was panicky. I was a little nervous about what was going on. I was nervous at how susceptible I would be to it… I think COVID would kill me. I’ve already got a weakened immune system, and then the things that do I hear about it, you know, I have secondary hypertension, diabetes, um, nephrotic syndrome. (Respondent 044)

In part due to these health risks, some respondents described an initial decrease in their tobacco use during the early spread and awareness of COVID-19. However, often related to an acute stressor resulting from the pandemic conditions, respondents described relapses.

Well, from June [2020] I went back down again. When me and my doctor, we first started I think it was in September that we started. And, like in October because I’m taking these pills of Bupropion, and they were helping like a little bit. One point, I was down to like, like four cigarettes a day. And then maybe end of October, I had, I had tragedy in my family. I picked up smoking a little more after that. (Respondent 110)

I’d stopped like somewhere in May and I was doing good. And then when I got the call about my brother in-law, and that made me go out straight to the store and buy a pack of cigarette. Now, that’s the time I was smoking cigarette one after another because I couldn’t get over, you know, what happened to my brother in-law and that’s how it all started. (Respondent 115)

And then we moved here and I started smoking again, because I was so worried. My nerves are so bad that I was worried about us paying the rent because we’re paying that like almost double of the rent we were paying before. (Respondent 122)

Discussion

Our results indicate that, for many respondents, increases in perceived stress and social isolation may have been associated with increased tobacco use during the COVID-19 pandemic. While smoking is associated with increased severity of COVID-19 symptoms [1, 2, 4] and worse outcomes [29], respondents did not appear to rely on the emerging scientific evidence to inform this opinion. In contrast, their perceptions of illness and resulting personal health risks were based on personal experience. While many respondents felt that smoking relieved their stress from the pandemic, they appeared unaware of the stress-inducing properties of tobacco use [4]. Therefore, a possible explanation for increased tobacco use, despite this increased risk perception, is that many individuals relied on tobacco as a maladaptive coping tool in the face of acute stress. Because acute stress was increased during the pandemic, this may have further exacerbated tobacco use patterns and may have prevented quit attempts despite the “teachable moment” of tobacco-associated COVID-19 risk.

In other settings, near-term health threats have been effective in promoting tobacco treatment uptake and smoking cessation. For example, lung cancer screening is applicable to patients with many years of tobacco use and as many as half continue to use tobacco at the time of screening [30]. Tobacco treatments are successful in the context of lung cancer screening because of the inherent health and mortality threat patients confront when undergoing the annual screening which is explicitly performed to detect life-threatening cancer [31, 32]. Therefore, a health threat (risk of cancer) becomes a strategic moment for patients who may approach tobacco cessation as carrying immediate health benefits. However, our results suggest that tobacco treatment efforts in the context of health-related stress may be augmented by including specific stress management tools. In the case of COVID-19, which carried not just health threats but also immediate financial and social threats, integrating stress management interventions into tobacco treatment during this critical moment may have resulted in fewer patients increasing tobacco use in response.

The strengths of our study include the representation of patients from medically underserved groups and our use of qualitative methods to gain greater insight into the observed patterns of tobacco use during the pandemic [5, 7, 16]. Our study has limitations in addition to its strengths. First, our participants were recruited from a single state (Pennsylvania). This is particularly important given state-specific COVID-19 policies and burdens during the period of study. However, Pennsylvania is a geographically and politically diverse state, and we developed recruitment processes to maximize the sample’s diversity. Second, we conducted cross-sectional interviews, such that we were unable to describe longitudinal patterns or changes in individuals’ perspectives. The study was purely observational, which limits our ability to assess causal mechanisms for increased tobacco use. COVID-related research restrictions included remote-only recruitment, which led to challenges in response rate as we relied on EHR documentation of contact information and mail and phone contacts only. However, such approaches also may have engaged patients who attended in-person appointments less regularly given that we relied on recruitment based on prior visits (i.e., panels of patients) rather than ongoing engagement with health care services. Future work in this area should consider utilizing the concepts we identified as salient to develop a large-scale survey that would allow for statistical comparisons and analyses.

Conclusion

Perceived stress is a well-described risk factor for tobacco smoking and a barrier to successful smoking cessation. Our findings indicate that there were varied responses to the COVID-19 pandemic among older, medically underserved people who smoked. Given the COVID-19 pandemic brought associated health, social, financial, and other stressors, these may have overpowered the health-related motivations to quit smoking due to reliance on tobacco as a maladaptive coping tool. Results may assist clinicians in addressing the role of tobacco use in response to highly stressful events.

Supporting information

S1 File. Interview guide.

(DOCX)

pone.0308966.s001.docx (35.8KB, docx)

Data Availability

The datasets generated and analyzed during the current study are not publicly available because informed consent stated that any data collected would not be used in future studies; however, de-identified data may be available from the PAIR Center Data Manager at pair@pennmedicine.upenn.edu on reasonable request.

Funding Statement

This project was funded by the Patient Centered Outcomes Research Institute (PCORI) (PCORI ID: PCS-2018C1-11326 (JH)). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Mengin AC, Rolling J, Porche C, Durpoix A, Lalanne L. The intertwining of posttraumatic stress symptoms, alcohol, tobacco or nicotine use, and the COVID-19 pandemic: A systematic review. International Journal of Environmental Research and Public Health 2022. Nov 5,;19(21):14546. doi: 10.3390/ijerph192114546 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Fidler JA, West R. Self-perceived smoking motives and their correlates in a general population sample. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 2009. –10;11(10):1182–1188. [DOI] [PubMed] [Google Scholar]
  • 3.Lawless MH, Harrison KA, Grandits GA, Eberly LE, Allen SS. Perceived stress and smoking-related behaviors and symptomatology in male and female smokers. Addictive Behaviors 2015. –12;51:80–83. doi: 10.1016/j.addbeh.2015.07.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Parrott AC. Does cigarette smoking cause stress? The American Psychologist 1999. –10;54(10):817–820. doi: 10.1037//0003-066x.54.10.817 [DOI] [PubMed] [Google Scholar]
  • 5.Johnston E, Bains M, Hunter A, Langley T. The impact of the COVID-19 pandemic on smoking, vaping, and smoking cessation services in the united kingdom: A qualitative study. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 2023. -01-05;25(2):339–344. doi: 10.1093/ntr/ntac227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gravely S, Craig LV, Cummings KM, Ouimet J, Loewen R, Martin N, et al. Smokers’ cognitive and behavioural reactions during the early phase of the COVID-19 pandemic: Findings from the 2020 ITC four country smoking and vaping survey. PLoS ONE 2021. June 4,;16(6):e0252427. doi: 10.1371/journal.pone.0252427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wang X, Ma Z, Wang C. A longitudinal study on the addictive behaviors of general population before and during the COVID-19 pandemic in china. International Journal of Environmental Research and Public Health 2022. -05-14;19(10):5979. doi: 10.3390/ijerph19105979 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Driezen P, Kasza KA, Gravely S, Thompson ME, Fong GT, Michael Cummings K, et al. Was COVID-19 associated with increased cigarette purchasing, consumption, and smoking at home among US smokers in early 2020? findings from the US arm of the international tobacco control (ITC) four country smoking and vaping survey. Addictive Behaviors 2022. –06;129:107276. doi: 10.1016/j.addbeh.2022.107276 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Tzu-Hsuan Chen D. The psychosocial impact of the COVID-19 pandemic on changes in smoking behavior: Evidence from a nationwide survey in the UK. Tobacco Prevention & Cessation 2020;6:59. doi: 10.18332/tpc/126976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Streck JM, Kalkhoran S, Bearnot B, Gupta PS, Kalagher KM, Regan S, et al. Perceived risk, attitudes, and behavior of cigarette smokers and nicotine vapers receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. Drug and Alcohol Dependence 2021. -01-01;218:108438. doi: 10.1016/j.drugalcdep.2020.108438 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kalkhoran SM, Levy DE, Rigotti NA. Smoking and E-cigarette use among U.S. adults during the COVID-19 pandemic. American Journal of Preventive Medicine 2022. March 1,;62(3):341–349. doi: 10.1016/j.amepre.2021.08.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Klemperer EM, West JC, Peasley-Miklus C, Villanti AC. Change in tobacco and electronic cigarette use and motivation to quit in response to COVID-19. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 2020. -08-24;22(9):1662–1663. doi: 10.1093/ntr/ntaa072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yach D. Tobacco use patterns in five countries during the COVID-19 lockdown. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 2020. -08-24;22(9):1671–1672. doi: 10.1093/ntr/ntaa097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Phetphum C, Prajongjeep A, Keeratisiroj O, Thawatchaijareonying K. Communication intervention to improve perceived threat of smoking-related COVID-19 and intentions to quit smoking during the COVID-19 pandemic in thailand. Tobacco Induced Diseases 2022;20:66. doi: 10.18332/tid/150363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Fosgaard TR, Pizzo A, Sadoff S. Sustained decline in tobacco purchasing in denmark during the COVID-19 pandemic. Communications Medicine 2022;2:96. doi: 10.1038/s43856-022-00160-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rigotti NA, Chang Y, Regan S, Lee S, Kelley JHK, Davis E, et al. Cigarette smoking and risk perceptions during the COVID-19 pandemic reported by recently hospitalized participants in a smoking cessation trial. Journal of General Internal Medicine 2021. December 1,;36(12):3786–3793. doi: 10.1007/s11606-021-06913-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Cordon M, Eyestone E, Hutchison S, Dunlap D, Smith L, Williams RM, et al. A qualitative study exploring older smokers’ attitudes and motivation toward quitting during the COVID-19 pandemic. Preventive Medicine Reports 2021. Jun 01,;22:101359. doi: 10.1016/j.pmedr.2021.101359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Av Dorn, Cooney RE Sabin ML. COVID-19 exacerbating inequalities in the US. Lancet (London, England) 2020. Apr 18,;395(10232):1243–1244. doi: 10.1016/S0140-6736(20)30893-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wiemers EE, Abrahams S, AlFakhri M, Hotz VJ, Schoeni RF, Seltzer JA. Disparities in vulnerability to severe complications from COVID-19 in the united states. medRxiv 2020. Jun 22,. doi: 10.1101/2020.05.28.20115899 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Cornelius ME. Tobacco product use among adults—united states, 2020. MMWR. Morbidity and Mortality Weekly Report 2022;71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Brown-Johnson CG, England LJ, Glantz SA, Ling PM. Tobacco industry marketing to low socio-economic status women in the US. Tobacco Control 2014. Jan 21,;23:e139–e146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Tobacco Control Legal Consortium. Evans v. lorillard: A bittersweet victory against the tobacco industry. Https://Publichealthlawcenter.Org/Sites/Default/Files/Resources/Tclc-Evans-V-Lorillard-Case-Study-2016.Pdf 2016;2023(Jul 7,).
  • 23.D’Angelo H, Ammerman A, Gordon-Larsen P, Linnan L, Lytle L, Ribisl KM. Sociodemographic disparities in proximity of schools to tobacco outlets and fast-food restaurants. American Journal of Public Health (1971) 2016. Sep;106(9):1556–1562. doi: 10.2105/AJPH.2016.303259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.[Anonymous]. FTC releases reports on 2015 cigarette and smokeless tobacco sales and marketing expenditures. Federal Trade Commission 2017 -10-25T12:33:55–04:00;2023(Jul 7,). [Google Scholar]
  • 25.[Anonymous]Designed for addiction: How the tobacco industry has made cigarettes more addictive, more attractive to kids and even more deadly.; 2014. June 23. [Google Scholar]
  • 26.Connolly GN, Alpert HR, Wayne GF, Koh H. Trends in nicotine yield in smoke and its relationship with design characteristics among popular US cigarette brands, 1997–2005. Tobacco Control 2007. /10/01;16(5):e5–e5. doi: 10.1136/tc.2006.019695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Agunwamba AA, Kawachi I, Williams DR, Finney Rutten LJ, Wilson PM, Viswanath K. Mental health, racial discrimination, and tobacco use differences across Rural‐Urban california. The Journal of Rural Health 2017;33(2):180–189. doi: 10.1111/jrh.12182 [DOI] [PubMed] [Google Scholar]
  • 28.Hennink M, Kaiser BN. Sample sizes for saturation in qualitative research: A systematic review of empirical tests. Social Science & Medicine 2022. January 1,;292:114523. doi: 10.1016/j.socscimed.2021.114523 [DOI] [PubMed] [Google Scholar]
  • 29.Bou Haddad C, Malhab S, Sacre H, Salameh P Smoking and COVID-19: A scoping review. Tob use Insights 2021. Feb 15,;14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Foley KL, Dressler EV, Weaver KE, Sutfin EL, Miller DP, Bellinger C, et al. The optimizing lung screening trial (WF-20817CD): Multicenter randomized effectiveness implementation trial to increase tobacco use cessation for individuals undergoing lung screening. Chest 2023. -03-15:S0012–0. doi: 10.1016/j.chest.2023.03.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ostroff JS, Buckshee N, Mancuso CA, Yankelevitz DF, Henschke CI. Smoking cessation following CT screening for early detection of lung cancer. Preventive Medicine 2001. –12;33(6):613–621. doi: 10.1006/pmed.2001.0935 [DOI] [PubMed] [Google Scholar]
  • 32.Clark MA, Gorelick JJ, Sicks JD, Park ER, Graham AL, Abrams DB, et al. The relations between false positive and negative screens and smoking cessation and relapse in the national lung screening trial: Implications for public health. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 2016. –01;18(1):17–24. doi: 10.1093/ntr/ntv037 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Enkeleint A Mechili

11 Jun 2024

PONE-D-24-07719Tobacco Use as Stress Relief During COVID-19PLOS ONE

Dear Dr. Klaiman,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 26 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Enkeleint A. Mechili

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. Please describe in your methods section how capacity to provide consent was determined for the participants in this study. Please also state whether your ethics committee or IRB approved this consent procedure. If you did not assess capacity to consent please briefly outline why this was not necessary in this case.

3. Thank you for stating the following financial disclosure: 

 [PCORI ID: PCS-2018C1-11326 (JH)].  

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. Please expand the acronym “PCORI” (PCORI ID: PCS-2018C1-11326 (JH)) so that it states the name of your funders in full.

This information should be included in your cover letter; we will change the online submission form on your behalf.

5. In the online submission form, you indicated that [The datasets generated and analyzed during the current study are not publicly available because informed consent stated that any data collected would not be used in future studies; however, de-identified data may be available from the corresponding author on reasonable request.]. 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

6. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

7. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

8. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

9. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: N/A

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The aim of the authors' study was to identify the impacts of the COVID-19 pandemic on tobacco use and preparedness for smoking cessation among individuals who smoke and are older and medically underserved. This work will assist clinicians understand the role of tobacco use in responding to high-stress events.

There are the following comments and suggestions:

1. The study was limited to Pennsylvania and was a cross-sectional survey. But the title of the article is "Tobacco Use as Stress Relief During COVID-19." So is this title not specific enough?

2. It is suggested to supplement the research methods: a) How to recruit people? b) Sample size; c) Interview topic list and whether everyone is interviewed according to the same interview topic list.

3. The author adopts a qualitative research method, and the data are presented by the interview focus and the discourse of the interviewee. Is it necessary to consider statistical analysis of the interview focus and interviewees' responses so as to better present the reliability of the results?

Reviewer #2: This was an interesting study with findings that are relevant to those within tobacco control. As this manuscript highlights, it would seem that there were missed opportunities during the pandemic to increase smoking cessation, particularly among populations like those identified in this paper who are already underserved and were/are at higher risk for COVID-19 infection and complications. I think I only have a couple of minor critiques for the authors to consider.

First, I would consider softening the causal sounding language in the Discussion section (e.g., "increases in stress...led to increased tobacco use") and any kind of reference to mechanism, given the study was both qualitative in nature and based on participant self-report. It may also be worth noting in the limitations that this study was purely observational.

Second, it may also be worth noting that not only were these observed coping patterns maladaptive, but I might emphasize that the behavior of smoking itself seems to put participants at increased risk of COVID-19 infection. For example, there is strong evidence that tobacco use increased risk of mortality and disease severity/progression among COVID-19 patients.

Reviewer #3: The sample size used by the author is too small to represent the entire population of smokers, leading to potential issues with the conclusions drawn from this data. Additionally, the data provided by the author mostly consists of subjective language descriptions from respondents, lacking scientific reliability.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Aug 19;19(8):e0308966. doi: 10.1371/journal.pone.0308966.r002

Author response to Decision Letter 0


29 Jul 2024

Response to Reviewers

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

Thank you, the formatting has been updated to adhere to the style requirements.

2. Please describe in your methods section how capacity to provide consent was determined for the participants in this study. Please also state whether your ethics committee or IRB approved this consent procedure. If you did not assess capacity to consent please briefly outline why this was not necessary in this case.

We have addressed this in the updated methods section. “Participants were given a full description of the study and agreed to participate after expressing understanding of the study procedures.”

3. Thank you for stating the following financial disclosure:

[PCORI ID: PCS-2018C1-11326 (JH)].

Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

This has been added to the cover letter.

4. Please expand the acronym “PCORI” (PCORI ID: PCS-2018C1-11326 (JH)) so that it states the name of your funders in full.

This information should be included in your cover letter; we will change the online submission form on your behalf.

We have updated the cover letter to include this information.

5. In the online submission form, you indicated that [The datasets generated and analyzed during the current study are not publicly available because informed consent stated that any data collected would not be used in future studies; however, de-identified data may be available from the corresponding author on reasonable request.].

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval.

Thank you. We contacted the University of Pennsylvania IRB who gave us guidance on this issue. We no longer have contact information for participants, and at the time they were consented, we were not required to include a future use statement in the consent form. We are not comfortable putting the data in a public repository without participant consent.

6. We note that you have indicated that there are restrictions to data sharing for this study. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

Before we proceed with your manuscript, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see

https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Thank you. As noted in the response to #6. We have contacted the University of Pennsylvania IRB to discuss this issue. We no longer have contact information for participants, and at the time they were consented, we were not required to include a future use statement in the consent form. We are not comfortable putting the data in a public repository without participant consent.

7. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

We have updated the title in the manuscript to reflect the title in the online submission form.

8. Please amend either the abstract on the online submission form (via Edit Submission) or the abstract in the manuscript so that they are identical.

The abstract has been updated for consistency.

9. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

We have included a caption for our Supporting Information files..

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The aim of the authors' study was to identify the impacts of the COVID-19 pandemic on tobacco use and preparedness for smoking cessation among individuals who smoke and are older and medically underserved. This work will assist clinicians understand the role of tobacco use in responding to high-stress events.

There are the following comments and suggestions:

1. The study was limited to Pennsylvania and was a cross-sectional survey. But the title of the article is "Tobacco Use as Stress Relief During COVID-19." So is this title not specific enough?

We have updated the title to “Use of Tobacco During COVID-19: A Qualitative Study among Medically Underserved Individuals.”

2. It is suggested to supplement the research methods: a) How to recruit people? b) Sample size; c) Interview topic list and whether everyone is interviewed according to the same interview topic list.

Thank you for your feedback.

a) We have described our recruitment strategy in greater detail in the methods section.

b) We described the sample size and demographics in the results section.

c) We have noted that all respondents were asked questions about the key topics specified in the methods section.

3. The author adopts a qualitative research method, and the data are presented by the interview focus and the discourse of the interviewee. Is it necessary to consider statistical analysis of the interview focus and interviewees' responses so as to better present the reliability of the results?

Thank you for your suggestion. The purpose of the study was to learn about people’s behaviors and perspectives via in-depth interviews. The sample size is too small to conduct statistical analyses. We were interested in learning about peoples’ experiences directly from them, rather than testing hypotheses in a large sample. We have noted in the limitations section “Future work in this area should consider utilizing the concepts we identified as salient to develop a large-scale survey that would allow for statistical comparisons and analyses.”

Reviewer #2: This was an interesting study with findings that are relevant to those within tobacco control. As this manuscript highlights, it would seem that there were missed opportunities during the pandemic to increase smoking cessation, particularly among populations like those identified in this paper who are already underserved and were/are at higher risk for COVID-19 infection and complications. I think I only have a couple of minor critiques for the authors to consider.

First, I would consider softening the causal sounding language in the Discussion section (e.g., "increases in stress...led to increased tobacco use") and any kind of reference to mechanism, given the study was both qualitative in nature and based on participant self-report. It may also be worth noting in the limitations that this study was purely observational.

Thank you for your feedback. We have softened the language so as not to assume causal mechanisms. We have also noted in the limitations that “The study was purely observational, which limits our ability to assess causal mechanisms for increased tobacco use.”

Second, it may also be worth noting that not only were these observed coping patterns maladaptive, but I might emphasize that the behavior of smoking itself seems to put participants at increased risk of COVID-19 infection. For example, there is strong evidence that tobacco use increased risk of mortality and disease severity/progression among COVID-19 patients.

We have included that patients who smoke had worse outcomes from COVID-19 with a corresponding citation.

Reviewer #3: The sample size used by the author is too small to represent the entire population of smokers, leading to potential issues with the conclusions drawn from this data. Additionally, the data provided by the author mostly consists of subjective language descriptions from respondents, lacking scientific reliability.

This is a qualitative study using reliable scientific qualitative methods. We were interested in learning about peoples’ experiences directly from them, rather than testing hypotheses in a large sample.

Attachment

Submitted filename: Response to Reviewers07232024.docx

pone.0308966.s002.docx (19.8KB, docx)

Decision Letter 1

Enkeleint A Mechili

5 Aug 2024

Use of Tobacco During COVID-19: A Qualitative Study among Medically Underserved Individuals

PONE-D-24-07719R1

Dear Dr. Klaiman,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Enkeleint A. Mechili

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Enkeleint A Mechili

8 Aug 2024

PONE-D-24-07719R1

PLOS ONE

Dear Dr. Klaiman,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Assoc. Dr. Enkeleint A. Mechili

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Interview guide.

    (DOCX)

    pone.0308966.s001.docx (35.8KB, docx)
    Attachment

    Submitted filename: Response to Reviewers07232024.docx

    pone.0308966.s002.docx (19.8KB, docx)

    Data Availability Statement

    The datasets generated and analyzed during the current study are not publicly available because informed consent stated that any data collected would not be used in future studies; however, de-identified data may be available from the PAIR Center Data Manager at pair@pennmedicine.upenn.edu on reasonable request.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES